Osteonecrosis of the femoral head—commonly called avascular necrosis of the hip—represents one of the most challenging orthopedic conditions facing young and middle-aged adults. When the blood supply to the femoral head is compromised, bone tissue begins to die, often leading to joint collapse and the eventual need for total hip replacement. For patients in early-to-mid-stage disease, joint-preserving treatments offer hope of delaying or avoiding surgery entirely. A comprehensive network meta-analysis published in July 2026 brings new clarity to how these conservative options compare, with hyperbaric oxygen therapy emerging as a particularly noteworthy contender.
The Burden of Hip Osteonecrosis
Osteonecrosis of the femoral head affects approximately 10,000 to 20,000 new patients annually in the United States alone, with a disproportionate impact on adults between ages 30 and 50. The condition stems from interrupted blood flow to the subchondral bone, triggering a cascade of ischemia, bone marrow cell death, and eventual structural collapse. Corticosteroid use, alcohol consumption, trauma, and certain medical conditions like sickle cell disease rank among the primary risk factors.
The economic and quality-of-life implications are substantial. Total hip arthroplasty, while effective, carries significant costs and may require revision surgery within 15–20 years—particularly problematic for younger patients who face multiple surgeries over their lifetime. This reality has driven sustained interest in joint-preserving strategies that can halt disease progression before irreversible joint destruction occurs.
Joint-Preserving Treatment Landscape
The July 2026 network meta-analysis, published in Frontiers in Cell and Developmental Biology, systematically evaluated five major joint-preserving approaches: core decompression, cell-based therapy, extracorporeal shock wave therapy (ESWT), hyperbaric oxygen therapy (HBOT), and various combination regimens. The research team from Guangzhou University of Chinese Medicine and The Third Affiliated Hospital analyzed 29 studies encompassing randomized controlled trials and retrospective comparative studies, applying rigorous PRISMA-NMA guidelines and prospectively registering their protocol with PROSPERO.
Core decompression—the mechanical drilling of channels into the necrotic bone to reduce intraosseous pressure and stimulate healing—has long served as the surgical standard for early-stage disease. Cell-based therapies, encompassing bone marrow-derived mesenchymal stem cells and other cellular approaches, have gained traction as biological augmentation. Extracorporeal shock wave therapy delivers acoustic pulses intended to stimulate neovascularization and osteogenesis. Hyperbaric oxygen therapy, meanwhile, leverages pressurized 100% oxygen to enhance tissue oxygenation and promote angiogenesis in ischemic bone.
What the Evidence Shows
The network meta-analysis employed multiple outcome measures to assess comparative effectiveness. Primary endpoints included the Harris Hip Score—a widely validated clinician-assessed measure of hip function—and imaging progression as determined by MRI or X-ray staging systems. Secondary outcomes encompassed conversion to total hip arthroplasty, patient-reported measures including the Oxford Hip Score and SF-36 quality-of-life instrument, WOMAC osteoarthritis indices, and documented adverse events.
Treatment rankings using the Surface Under the Cumulative Ranking Curve (SUCRA) methodology provided probabilistic assessments of which interventions performed best across outcomes. The analysis also incorporated GRADE assessments of evidence certainty and rigorous risk-of-bias evaluation using RoB 2.0 for randomized trials and ROBINS-I for observational studies.
While the full statistical outputs require careful interpretation, the study’s comparative framework represents the most comprehensive attempt to date at ranking these modalities against one another rather than simply against placebo or no treatment. This network approach allows indirect comparisons between treatments that have never been head-to-head in randomized trials—a critical advantage given the fragmented nature of orthopedic evidence.
Hyperbaric Oxygen’s Mechanistic Rationale
The biological plausibility for HBOT in osteonecrosis rests on well-established physiological principles. Under hyperbaric conditions—typically 2.0 to 2.5 atmospheres absolute—oxygen dissolves directly into plasma at concentrations sufficient to sustain cellular metabolism independent of hemoglobin-bound oxygen. This hyperoxygenation extends diffusion gradients, enabling oxygen delivery to ischemic tissues beyond the reach of compromised microcirculation.
For osteonecrotic bone, enhanced oxygen delivery serves multiple therapeutic purposes. It supports the metabolic demands of reparative cells attempting to rebuild damaged matrix. It promotes angiogenesis through upregulation of vascular endothelial growth factor and other pro-angiogenic signaling pathways. It modulates inflammatory responses that can perpetuate tissue damage. And it may improve osteoclast-osteoblast coupling, facilitating the remodeling necessary for structural restoration.
These mechanisms align with HBOT’s established efficacy in other ischemic conditions, including delayed radiation injury and compromised grafts—both FDA-cleared indications where tissue hypoxia drives pathology.
The FDA Context: Cleared vs. Investigated Uses
Understanding where osteonecrosis fits within HBOT’s regulatory landscape is essential for balanced interpretation. The FDA has cleared hyperbaric oxygen therapy for thirteen specific indications: air or gas embolism, carbon monoxide poisoning, decompression sickness, clostridial myonecrosis (gas gangrene), crush injury and acute traumatic ischemias, diabetic foot ulcers, enhanced healing of selected problem wounds, exceptional blood loss anemia, intracranial abscess, necrotizing soft tissue infections, osteomyelitis (refractory), delayed radiation injury, and compromised skin grafts and flaps.
Osteonecrosis of the femoral head does not appear on this list. The FDA explicitly states that HBOT is “not FDA cleared” for conditions including cancer, autism, Alzheimer’s disease, Lyme disease, cerebral palsy, multiple sclerosis, stroke, asthma, heart disease—and osteonecrosis. This regulatory status does not imply that research is futile or that evidence is absent; rather, it indicates that the therapy has not undergone the rigorous premarket review process required for formal clearance for this specific indication.
The August 2025 FDA safety letter to healthcare providers adds another layer of consideration, emphasizing fire risks and the importance of following manufacturer instructions for chamber operation. This communication followed reports of injuries and deaths associated with improper HBOT device use, underscoring that even investigational applications must adhere to strict safety protocols.
Evidence Quality and Clinical Decision-Making
The network meta-analysis’s GRADE assessments provide crucial context for interpreting findings. Not all evidence in orthopedic surgery meets high certainty standards—randomized trials are relatively scarce, follow-up durations vary, and outcome measurement lacks standardization across studies. The research team appropriately flagged these limitations, noting that sparse networks required fixed-effect modeling in some comparisons and that cellular therapies varied considerably in source, preparation, dose, and delivery method.
For clinicians and patients considering joint-preserving options, these evidence limitations matter. Network meta-analyses can rank treatments probabilistically, but they cannot substitute for large, well-conducted randomized trials with long-term follow-up. The osteonecrosis literature particularly lacks standardized definitions of disease progression and consistent criteria for conversion to arthroplasty, complicating cross-study comparisons.
Practical Implications for Patients
For individuals diagnosed with early-stage osteonecrosis, the treatment decision involves weighing multiple factors beyond comparative efficacy rankings. Disease stage at presentation—typically classified using the Steinberg or ARCO systems—heavily influences prognosis regardless of intervention. Lesion size, location within the femoral head, and presence of subchondral collapse all modulate treatment response. Patient age, activity demands, and comorbidities further personalize the risk-benefit calculus.
Hyperbaric oxygen therapy offers certain practical advantages in this context. It is non-invasive, avoiding surgical morbidity associated with core decompression or cell harvesting. Treatment protocols typically involve daily 90-minute sessions at 2.0–2.5 ATA over 4–6 weeks—a substantial time commitment, but one that preserves normal activity between sessions. Side effects are generally mild when protocols are followed, with middle ear barotrauma and temporary visual changes representing the most common issues.
However, HBOT’s off-label status means insurance coverage is inconsistent. Patients may face substantial out-of-pocket costs, and access requires locating facilities with appropriate chamber capabilities and experience treating orthopedic conditions. These practical barriers limit widespread adoption regardless of clinical potential.
The Path Forward
The July 2026 network meta-analysis contributes meaningfully to an evidence base that has long suffered from fragmentation and methodological heterogeneity. By synthesizing direct and indirect comparisons across multiple modalities, the study offers clinicians a more nuanced framework for treatment selection than any individual trial could provide.
For hyperbaric oxygen therapy specifically, the findings suggest continued research investment is warranted. Well-designed randomized trials comparing HBOT against established alternatives, with standardized outcome measures and adequate follow-up duration, would address the evidence gaps that currently limit regulatory advancement. Biomarker studies exploring angiogenic response, bone turnover markers, and imaging correlates of treatment effect could illuminate which patients are most likely to benefit.
The broader orthopedic community would benefit from consensus definitions of treatment success in joint-preserving osteonecrosis management. Without standardized endpoints, studies remain difficult to compare and synthesize, perpetuating uncertainty about optimal care pathways.
Conclusion
Osteonecrosis of the femoral head remains a formidable clinical challenge, particularly for younger patients seeking to delay or avoid joint replacement. The July 2026 network meta-analysis represents a significant methodological advance in comparing joint-preserving options, positioning hyperbaric oxygen therapy within a broader therapeutic landscape that includes core decompression, cellular therapies, and shock wave treatment.
While the evidence base continues to evolve, patients and clinicians must navigate current uncertainties with clear-eyed understanding of both potential benefits and regulatory realities. HBOT’s off-label status for osteonecrosis does not preclude consideration as part of a comprehensive joint-preservation strategy, but it does require informed discussion about evidence limitations, cost implications, and the safety considerations emphasized in recent FDA communications. For now, treatment decisions should reflect individual patient factors, disease characteristics, and realistic expectations about what current evidence can—and cannot—tell us about optimal care.